Preclinical studies suggest that GLP-1 RAs can reduce oxidative stress, enhance axonal regeneration, and improve nerve conduction
Eli Lilly: Accounts for nearly 12%15% market share
Looking forward, the GLP-1 drugs we study (semaglutide, tirzepatide, and emerging oral formulations like orforglipron) are likely only the beginning of a new wave of chronic therapies for conditions like obesity, heart failure, and even kidney disease
All products are chemical reference materials sold for in-vitro laboratory research use only
Mismatched needles risk leakage, improper dosing, or injection site trauma
May increase dose in 2.5 mg/week increments every 4 weeks if needed to achieve glycemic goals (maximum weekly dose: 15 mg/week)